von Roemeling C, Wang Y, Qie Y, Yuan H, Zhao H, Liu X, et al. Therapeutic modulation of phagocytosis in glioblastoma can activate both innate and adaptive antitumour immunity. Nat Commun. 2020;11:1508 pubmed publisher

Cui L, Chen S, Lerbs T, Lee J, Domizi P, Gordon S, et al. Activation of JUN in fibroblasts promotes pro-fibrotic programme and modulates protective immunity. Nat Commun. 2020;11:2795 pubmed publisher

Tsao L, Crosby E, Trotter T, Agarwal P, Hwang B, Acharya C, et al. CD47 blockade augmentation of trastuzumab antitumor efficacy dependent on antibody-dependent cellular phagocytosis. JCI Insight. 2019;4: pubmed publisher

Engelbertsen D, Autio A, Verwilligen R, Depuydt M, Newton G, Rattik S, et al. Increased lymphocyte activation and atherosclerosis in CD47-deficient mice. Sci Rep. 2019;9:10608 pubmed publisher

Kojima Y, Werner N, Ye J, Nanda V, Tsao N, Wang Y, et al. Proefferocytic Therapy Promotes Transforming Growth Factor-? Signaling and Prevents Aneurysm Formation. Circulation. 2018;137:750-753 pubmed publisher

Kojima Y, Volkmer J, McKenna K, Civelek M, Lusis A, Miller C, et al. CD47-blocking antibodies restore phagocytosis and prevent atherosclerosis. Nature. 2016;536:86-90 pubmed

Willingham S, Volkmer J, Gentles A, Sahoo D, Dalerba P, Mitra S, et al. The CD47-signal regulatory protein alpha (SIRPa) interaction is a therapeutic target for human solid tumors. Proc Natl Acad Sci U S A. 2012;109:6662-7 pubmed publisher

Han X, Sterling H, Chen Y, Saginario C, Brown E, Frazier W, et al. CD47, a ligand for the macrophage fusion receptor, participates in macrophage multinucleation. J Biol Chem. 2000;275:37984-92 pubmed